Pharmaceuticals

A new collaboration will use Voro's 'masking' technology to create tumor-activated ADCs, aiming to make powerful cancer therapies safer and more effective.

Galectin Therapeutics adds legendary neurosurgeon Dr. Henry Brem to its board, a strategic move to leverage his drug development expertise for its lead liver drug.

Exiting stealth, PerturbAI releases an 8-million-cell map of gene function in a living brain, aiming to slash the cost and time of creating new drugs.

Backed by dialysis giants DaVita and U.S. Renal Care, a new startup licenses a first-in-class therapy to transform treatment for kidney patients.

A new telehealth model challenges the prescription-first approach, combining GLP-1s with 24/7 clinical support. Is this the future of metabolic health?

UK biotech Alchemab hires Sanofi's Ulrich Wendt as CBO to forge major pharma deals for its novel AI platform that mines the secrets of human resilience.

A new alliance aims to overhaul Alzheimer's research, demanding a precision approach for the 65% of patients carrying the high-risk APOE4 gene.

A new compound could make CAR-T cell therapy more durable and less costly, showing promise against both cancer and HIV in groundbreaking new research.

With its lead autoimmune drug nearing FDA review and a new $250M in funding, Zenas BioPharma prepares for a major leap from R&D to market.

Inc. names Tiffany Whitlow to its Female Founders 500, validating Acclinate's model of making inclusive clinical research a profitable, high-growth venture.

Nasus Pharma's NS002 nasal spray reached critical therapeutic levels in half the time of EpiPen, heralding a potential new era for anaphylaxis treatment.

As MediciNova execs meet investors at the ROTH Conference, all eyes are on pivotal updates for its ALS, MS, and NAFLD drug candidates.

New data on an oral Parkinson's drug and major strides in rare disease research signal Lundbeck's deep commitment to tackling complex neurological disorders.

Actelion Pharmaceuticals settles a class action lawsuit for $65M, accused of illegally blocking a cheaper generic for its life-saving hypertension drug.

OTC-listed ProText Mobility unveils an audacious plan to tokenize biotech assets, partner with major banks, and uplist to a major exchange. Can it deliver?

As AI chips push power and heat limits, Compal debuts its "ONE Integrated Solution" at GTC 2026, a unified rack system aimed at defining the future of data centers.

A partnership between Biophytis and LynxKite leverages AI to fast-track therapies for sarcopenia and macular degeneration, backed by Singapore's RIE 2030 plan.

Western Alliance Bank launches a specialized healthcare banking division led by Jennifer Hwang, aiming to serve a complex and rapidly evolving industry.

As employers grapple with soaring obesity drug costs, a new partnership aims to offer predictable pricing and comprehensive care. Here's how it works.

The German biotech firm secured its Nasdaq listing, but a near-total investor redemption leaves its cancer-drug pipeline with less than $1M in trust funds.